Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
NCT01057693
Last updated date
ABOUT THIS STUDY
Patients will be switched from their current medication for painful diabetic peripheral
neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All
patients will receive pregabalin, and half of patients will receive placebo at some point
during the study.
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Painful Diabetic Neuropathy
Sex
Females and Males
Age
18 + years
Inclusion Criteria
Show details
- Patients must have painful diabetic peripheral neuropathy and be receiving treatment for this condition.
Exclusion Criteria
Show details
- Patients with other pain conditions cannot participate.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Painful Diabetic NeuropathyA Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
NCT00553280
- Nagoya, Aichi
- Date-shi, Fukushima
- Nihonmatsu, Fukushima
- Shirakawa-shi, Fukushima
- Sukagawa, Fukushima
- Kamakura, Kanagawa
- Yokohama, Kanagawa
- Sendai, Miyagi
- Matsumoto, Nagano
- Ueda, Nagano
- Beppu, Oita
- Yamada, Okayama
- Naha, Okinawa
- Tomishiro, Okinawa
- Urazoe, Okinawa
- Hirano-ku, Osaka
- Suminoe-ku, Osaka
- Sunto-gun, Shizuoka
- Oyama-shi, Tochigi
- Arakawa, Tokyo
- Bunkyo-ku, Tokyo
- Chiyoda-ku, Tokyo
- Ohta-ku, Tokyo
- Shibuya-ku, Tokyo
- Fukuoka,
- Oita,
- Tokushima,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Painful Diabetic NeuropathyRandomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
NCT00553475
- Nagoya, Aichi
- Chikushino, Fukuoka
- Kasuga, Fukuoka
- Date-shi, Fukushima
- Nihonmatsu, Fukushima
- Shirakawa-shi, Fukushima
- Sukagawa, Fukushima
- Kure, Hiroshima
- Chitose, Hokkaido
- Ebetu, Hokkaido
- Sapporo, Hokkaido
- Sapporo, Hokkaiido
- Kobe, Hyogo
- Inashiki, Ibaraki
- Kamakura, Kanagawa
- Yokohama, Kanagawa
- Yatsushiro, Kumamoto
- Sendai, Miyagi
- Matsumoto, Nagano
- Ueda, Nagano
- Beppu, Oita
- Yamada, Okayama
- Naha, Okinawa
- Tomishiro, Okinawa
- Urazoe, Okinawa
- Higashiosaka, Osaka
- Hirano-ku, Osaka
- Kishiwada, Osaka
- Suminoe-ku, Osaka
- Sunto-gun, Shizuoka
- Oyama-shi, Tochigi
- Utsunomiya, Tochigi
- Arakawa, Tokyo
- Bunkyo-ku, Tokyo
- Chiyoda-ku, Tokyo
- Chuo-ku, Tokyo
- Minato-ku, Tokyo
- Nishitokyo, Tokyo
- Ohta-ku, Tokyo
- Shibuya-ku, Tokyo
- Fukuoka,
- Kumamoto,
- Nagasaki,
- Niigata,
- Oita,
- Okayama,
- Saga,
- Saitama,
- Tokushima,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Painful Diabetic NeuropathyStudy Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
NCT01050218
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Painful Diabetic NeuropathyA Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)
NCT00156078
- Buenos Aires,
- Belo Horizonte, MG
- Niteroi, RJ
- Providencia, Santiago
- Valparaiso, V Region
- Medellin, Antioquia
- Bogotá, Cundinamarca
- Quito, Pichincha
- Jakarta Pusat,
- Surabaya,
- Amman,
- Pusan,
- Seoul,
- Beirut,
- Kuala Lumpur,
- Monterrey, Nuevo Leon
- Mexico Df,
- San Luis Potosi,
- Espana, Manila
- Quezon City,
- Riyadh,
- Singapore,
- Gueishan Shiang, Taoyan Hsien
- Taipei,
- Khet Rajathevee, Bangkok
- Muang, Chiang Mai
- Capa, Istanbul
- Ankara,
- Istanbul,
- Izmir,
- Mersin,
- Abu Dhabi,
- El Hatillo, Caracas-Estado Miranda
- Caracas, Distrito Capital
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy | ||||||
Official Title ICMJE | A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY | ||||||
Brief Summary | Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All patients will receive pregabalin, and half of patients will receive placebo at some point during the study. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | ||||||
Condition ICMJE | Diabetic Neuropathy, Painful | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Raskin P, Huffman C, Toth C, Asmus MJ, Messig M, Sanchez RJ, Pauer L. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain. 2014 May;30(5):379-90. doi: 10.1097/AJP.0b013e31829ea1a1. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE | 633 | ||||||
Original Estimated Enrollment ICMJE | 564 | ||||||
Actual Study Completion Date ICMJE | January 30, 2012 | ||||||
Actual Primary Completion Date | January 30, 2012 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Canada, Puerto Rico, South Africa, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT01057693 | ||||||
Other Study ID Numbers ICMJE | A0081242 2009-017389-21 ( EudraCT Number ) | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product | Not Provided | ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | ||||||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | February 2019 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |